Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

被引:11
|
作者
Abeyratne, Eranga [1 ]
Freitas, Joseph R. [1 ]
Zaid, Ali [1 ]
Mahalingam, Suresh [1 ]
Taylor, Adam [1 ]
机构
[1] Griffith Univ, Inst Glyc, Emerging Viruses & Inflammat Res Grp, Gold Coast, Qld 4222, Australia
基金
英国医学研究理事会;
关键词
alphavirus; chikungunya virus; live-attenuated; vaccine; preclinical; BURDEN; EPIDEMIOLOGY; INFECTION; DISEASE;
D O I
10.3390/vaccines7010002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS. CHIKV-NoLS-immunised mice developed long-term immunity from CHIKV infection after a single dose. To further evaluate CHIKV-NoLS attenuation and suitability as a vaccine, we examined the footpad of inoculated mice for underlying CHIKV-NoLS-induced immunopathology by histological and flow cytometric analysis. In comparison to CHIKV-WT-infected mice, CHIKV-NoLS-inoculated mice exhibited minimal inflammation and tissue damage. To examine the stability of attenuation, the plaque phenotype and replication kinetics of CHIKV-NoLS were determined following extended in vitro passage. The average plaque size of CHIKV-NoLS remained notably smaller than CHIKV-WT after extended passage and attenuated replication was maintained. To examine thermostability, CHIKV-NoLS was stored at 21 degrees C, 4 degrees C, -20 degrees C and -80 degrees C and infectious CHIKV-NoLS quantified up to 84 days. The infectious titre of CHIKV-NoLS remains stable after 56 days when stored at either -20 degrees C or -80 degrees C. Interestingly, unlike CHIKV-WT, the infectious titre of CHIKV-NoLS is not sensitive to freeze thaw cycles. These data further demonstrate preclinical safety and stability of CHIKV-NoLS.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Live-attenuated chikungunya virus vaccine
    Ng, Lisa F. P.
    Renia, Laurent
    CELL, 2024, 187 (04)
  • [2] Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate
    Plante, Kenneth S.
    Rossi, Shannan L.
    Bergren, Nicholas A.
    Seymour, Robert L.
    Weaver, Scott C.
    PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (09):
  • [3] Engineering a fidelity-variant live-attenuated vaccine for chikungunya virus
    Christopher M. Weiss
    Hongwei Liu
    Kasen K. Riemersma
    Erin E. Ball
    Lark L. Coffey
    npj Vaccines, 5
  • [4] Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate
    Chan, Yi-Hao
    Teo, Teck-Hui
    Utt, Age
    Tan, Jeslin J. L.
    Amrun, Siti Naqiah
    Abu Bakar, Farhana
    Yee, Wearn-Xin
    Becht, Etienne
    Lee, Cheryl Yi-Pin
    Lee, Bernett
    Rajarethinam, Ravisankar
    Newell, Evan
    Merits, Andres
    Carissimo, Guillaume
    Lum, Fok-Moon
    Ng, Lisa F. P.
    EMBO MOLECULAR MEDICINE, 2019, 11 (06)
  • [7] Engineering a fidelity-variant live-attenuated vaccine for chikungunya virus
    Weiss, Christopher M.
    Liu, Hongwei
    Riemersma, Kasen K.
    Ball, Erin E.
    Coffey, Lark L.
    NPJ VACCINES, 2020, 5 (01)
  • [8] New method of live-attenuated vaccine creation utilized for chikungunya virus
    Rees, Jenaid
    FUTURE VIROLOGY, 2013, 8 (04) : 329 - 329
  • [9] A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice
    Rao, Shambhavi
    Abeyratne, Eranga
    Freitas, Joseph R.
    Yang, Chenying
    Tharmarajah, Kothila
    Mostafavi, Helen
    Liu, Xiang
    Zaman, Mehfuz
    Mahalingam, Suresh
    Zaid, Ali
    Taylor, Adam
    VACCINE, 2023, 41 (27) : 3976 - 3988
  • [10] Live-attenuated Chikungunya vaccine: a possible new era
    Stephenson, Kathryn E.
    LANCET, 2023, 401 (10394): : 2090 - 2091